Photo of Alexi A. Wright,  MD, MPH

Alexi A. Wright, MD, MPH

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-3857
Fax: (617) 632-3479


alexi_wright@dfci.harvard.edu

Alexi A. Wright, MD, MPH

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Assistant Professor, Medical Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am a medical oncologist specializing in gynecologic oncology and a health outcomes researcher who studies the “overuse” of medical care in patients with advanced, incurable cancers. The goal of my research is to improve advanced cancer patients’ quality of life and medical outcomes by 1) creating an evidence base to guide chemotherapy decision-making at the end-of-life (EOL) and 2) developing interventions to ensure that advanced cancer patients’ EOL care is effective, patient-centered, and congruent with patients’ informed treatment preferences.

My early training in journalism gave me an appreciation for the power of effective communication, and its potential for improving patient outcomes. In medical school, I was awarded a Howard Hughes fellowship to examine the genotype of human placental cells that invade the uterus like tumors. This early research experience resulted in two empiric publications and cemented my decision to become an academic oncologist. During fellowship, I examined how EOL discussions shape advanced cancer patients’ mental health, medical outcomes, treatment goal attainment, and health care expenditures. We found that EOL discussions were associated with greater patient acceptance of terminal illness, better patient quality of life near death, and fewer intensive interventions at the EOL.

As a junior faculty member, I examined how patients’ place of death influences their quality of life at the EOL and their caregivers’ bereavement adjustment. We found that patients who die in intensive care units have significantly worse quality of life, compared to those who died at home with hospice, and their caregivers have 15-fold higher odds of developing post-traumatic stress disorder six months later. More recently, I have found that palliative chemotherapy is one of the most powerful predictors of the intensity of patients’ EOL care, and I am now focusing on understanding the structural, medical, social, and psychological determinants and outcomes of EOL chemotherapy with support from the American Cancer Society and the National Cancer Institute.

Communication is also a central focus of my work as an educator. As a junior faculty member, I have organized the Dana-Farber/Harvard Cancer Center’s Outcomes Research Seminar, and participated in OncoTalk Teach, an intensive communication course designed to teach oncologists how to 1) communicate more effectively with patients and 2) teach these skills to other physicians. This training has shaped my clinical work and educational work with medical residents and oncology fellows, improving my ability to offer “goal-directed” teaching and feedback. In the future, I plan to develop patient- and provider-based communication interventions to ensure that advanced cancer patients’ treatment decision-making and medical care reflect their informed preferences.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Fenton ATHR, Keating NL, Ornstein KA, Kent EE, Litzelman K, Rowland JH, Wright AA. Comparing adult-child and spousal caregiver burden and potential contributors. Cancer 2022; 128:2015-2024. PubMed
  • Knoerl R, Giobbie-Hurder A, Berfield J, Berry D, Meyerhardt J, Wright A, Ligibel J. Exploring Daily Salivary Cortisol Patterns as Biomarkers of Chronic Chemotherapy-Induced Peripheral Neuropathy Pain. Oncol Nurs Forum 2022; 49:207-211. PubMed
  • Keating NL, Landrum MB, Samuel-Ryals C, Sinaiko AD, Wright A, Brooks GA, Bai B, Zaslavsky AM. Measuring Racial Inequities In The Quality Of Care Across Oncology Practices In The US. Health Aff (Millwood) 2022; 41:598-606. PubMed
  • Konstantinopoulos PA, Cheng SC, Supko JG, Polak M, Wahner-Hendrickson AE, Ivy SP, Bowes B, Sawyer H, Basada P, Hayes M, Curtis J, Horowitz N, Wright AA, Campos SM, Ivanova EV, Paweletz CP, Palakurthi S, Liu JF, D'Andrea AD, Gokhale PC, Chowdhury D, Matulonis UA, Shapiro GI. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br J Cancer 2022; 126:1027-1036. PubMed
  • Pozzar RA, Enzinger AC, Poort H, Furey A, Donovan H, Orechia M, Thompson E, Tavormina A, Fenton ATHR, Jaung T, Braun IM, DeMarsh A, Cooley ME, Wright AA. Developing and Field Testing BOLSTER: A Nurse-Led Care Management Intervention to Support Patients and Caregivers following Hospitalization for Gynecologic Cancer-Associated Peritoneal Carcinomatosis. J Palliat Med 2022. PubMed
  • Cham S, Landrum MB, Keating NL, Armstrong J, Wright AA. Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance. JAMA Netw Open 2022; 5:e2142703. PubMed
  • Pozzar RA, Xiong N, Hong F, Wright AA, Goff BA, Underhill-Blazey ML, Tulsky JA, Hammer MJ, Berry DL. Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer. Gynecol Oncol 2021; 163:408-418. PubMed
  • Knoerl R, Giobbie-Hurder A, Berfield J, Berry D, Meyerhardt JA, Wright AA, Ligibel JA. Yoga for chronic chemotherapy-induced peripheral neuropathy pain: a pilot, randomized controlled trial. J Cancer Surviv 2021. PubMed
  • Enzinger AC, Ghosh K, Keating NL, Cutler DM, Landrum MB, Wright AA. US Trends in Opioid Access Among Patients With Poor Prognosis Cancer Near the End-of-Life. J Clin Oncol 2021. PubMed
  • Liu JF, Xiong N, Campos SM, Wright AA, Krasner C, Schumer S, Horowitz N, Veneris J, Tayob N, Morrissey S, West G, Quinn R, Matulonis UA, Konstantinopoulos PA. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol 2021; 39:1531-1539. PubMed
  • Gondi S, Wright AA, Landrum MB, Meneades L, Zubizarreta J, Chernew ME, Keating NL. Assessment of Patient Attribution to Care From Medical Oncologists, Surgeons, or Radiation Oncologists After Newly Diagnosed Cancer. JAMA Netw Open 2021; 4:e218055. PubMed
  • Lee G, Dee EC, Orav EJ, Kim DW, Nguyen PL, Wright AA, Lam MB. Association of Medicaid expansion and insurance status, cancer stage, treatment and mortality among patients with cervical cancer. Cancer Rep (Hoboken) 2021. PubMed
  • Azizoddin DR, Adam R, Kessler D, Wright AA, Kematick B, Sullivan C, Zhang H, Hassett MJ, Cooley ME, Ehrlich O, Enzinger AC. Leveraging mobile health technology and research methodology to optimize patient education and self-management support for advanced cancer pain. Support Care Cancer 2021. PubMed
  • Keating NL, Cleveland JLF, Wright AA, Brooks GA, Meneades L, Riedel L, Zubizarreta JR, Landrum MB. Evaluation of Reliability and Correlations of Quality Measures in Cancer Care. JAMA Netw Open 2021; 4:e212474. PubMed
  • Schrier E, Xiong N, Thompson E, Poort H, Schumer S, Liu JF, Krasner C, Campos SM, Horowitz NS, Feltmate C, Konstantinopoulos PA, Dinardo MM, Tayob N, Matulonis UA, Patel M, Wright AA. Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol 2021. PubMed
  • Kurtz JE, Gebski V, Sukhin V, Carey M, Kong I, Glasspool RM, Berek JS, de Paiva Batista M, Hall M, Kim JW, Yeoshoua E, Fujiwara N, Nam BH, Polleis S, Lee JY, Strojna A, Farrelly L, Schwameis R, Fossati R, Darlington AS, Lai CH, Wright AA, Rosenblat O, Harter P, Roxburgh P, Chowdhury RR, Chang TC, Paoletti X, Friedlander M, . Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. Gynecol Oncol 2021. PubMed
  • Rana HQ, Kipnis L, Hehir K, Cronin A, Jaung T, Stokes SM, Fekrmandi F, Vatnick D, Matulonis UA, Garber JE, Wright AA. Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer. Gynecol Oncol 2021; 160:457-463. PubMed
  • Seguin CL, Lietz AP, Wright JD, Wright AA, Knudsen AB, Pandharipande PV. Surveillance in Older Women With Incidental Ovarian Cysts: Maximal Projected Benefits by Age and Comorbidity Level. J Am Coll Radiol 2021; 18:10-18. PubMed
  • Poort H, Fenton ATHR, Thompson E, Dinardo MM, Liu JF, Arch JJ, Wright AA. Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study. Gynecol Oncol 2021; 160:227-233. PubMed
  • Braun IM, Nayak MM, Revette A, Wright AA, Chai PR, Yusufov M, Pirl WF, Tulsky JA. Cancer patients' experiences with medicinal cannabis-related care. Cancer 2020. PubMed
  • Enzinger AC, Wright AA. Reduced opioid prescribing by oncologists: progress made, or ground lost? Journal of the National Cancer Institute 2020. PubMed
  • Lee EK, Xiong N, Cheng SC, Barry WT, Penson RT, Konstantinopoulos PA, Hoffman MA, Horowitz N, Dizon DS, Stover EH, Wright AA, Campos SM, Krasner C, Morrissey S, Whalen C, Quinn R, Matulonis UA, Liu JF. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol 2020. PubMed
  • Poort H, de Rooij BH, Uno H, Weng S, Ezendam NPM, van de Poll-Franse L, Wright AA. Patterns and predictors of cancer-related fatigue in ovarian and endometrial cancers: 1-year longitudinal study. Cancer 2020. PubMed
  • Azizoddin DR, Enzinger AC, Wright AA, Yusufov M, Tulsky JA, Campbell EG, Bolcic-Jankovic D, Nayak MM, Braun IM. Oncologists' perspectives on medical marijuana use by older adults. 2020. PubMed
  • Pozzar R, Hammer MJ, Underhill-Blazey M, Wright AA, Tulsky JA, Hong F, Gundersen DA, Berry DL. Threats of Bots and Other Bad Actors to Data Quality Following Research Participant Recruitment Through Social Media: Cross-Sectional Questionnaire. J Med Internet Res 2020; 22:e23021. PubMed
  • Brizzi K, Zupanc SN, Udelsman BV, Tulsky JA, Wright AA, Poort H, Lindvall C. Natural Language Processing to Assess Palliative Care and End-of-Life Process Measures in Patients With Breast Cancer With Leptomeningeal Disease. Am J Hosp Palliat Care 2019. PubMed
  • Gondi S, Wright AA, Landrum MB, Zubizarreta J, Chernew ME, Keating NL. Multimodality cancer care and implications for episode-based payments in cancer. Am J Manag Care 2019; 25:537-538. PubMed
  • Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol 2019. PubMed
  • Poort H, Zupanc SN, Leiter RE, Wright AA, Lindvall C. Documentation of Palliative and End-of-Life Care Process Measures Among Young Adults Who Died of Cancer: A Natural Language Processing Approach. J Adolesc Young Adult Oncol 2019. PubMed
  • Lee EK, Tan-Wasielewski Z, Matulonis UA, Birrer MJ, Wright AA, Horowitz N, Konstantinopoulos PA, Curtis J, Liu JF. Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol Rep 2019; 29:118-122. PubMed
  • Liu JF, Gray KP, Wright AA, Campos S, Konstantinopoulos PA, Peralta A, MacNeill K, Morrissey S, Whalen C, Dillon D, Matulonis UA. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol 2019; 154:95-101. PubMed
  • Gockley A, Melamed A, Cronin A, Bookman MA, Burger RA, Cristae MC, Griggs JJ, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland J, O'Malley DM, Wright AA. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer. Am J Obstet Gynecol 2019. PubMed
  • Hungr C, Recklitis CJ, Wright AA, Bober SL. How does a single session group intervention improve sexual function in ovarian cancer survivors? A secondary analysis of effects of self-efficacy, knowledge and emotional distress. Psychol Health Med 2019. PubMed
  • Braun IM, Blonquist TM, Campbell EG, Nayak MM, Bolcic-Jankovic D, Wright AA. Medical Oncologists' Views on the Utility of Medical Marijuana Across the Cancer Trajectory. J Pain Symptom Manage 2019. PubMed
  • Lietz AP, Weaver DT, Melamed A, Rauh-Hain JA, Wright JD, Wright AA, Knudsen AB, Pandharipande PV. Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model. PLoS ONE 2019; 14:e0222828. PubMed
  • Hoogland AI, Bulls HW, Gonzalez BD, Wright AA, Kennedy B, Small BJ, Chahal N, Arboleda BL, Jim HSL. Differential patterns of circadian rhythmicity in women with malignant versus benign gynecologic tumors. 2018. PubMed
  • Meyer LA, He W, Sun CC, Zhao H, Wright AA, Suidan RS, Dottino J, Alejandro Rauh-Hain J, Lu KH, Giordano SH. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol 2018. PubMed
  • Melamed A, Fink G, Wright AA, Keating NL, Gockley AA, Del Carmen MG, Schorge JO, Rauh-Hain JA. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study. BMJ 2018; 360:j5463. PubMed
  • Markt SC, Tang T, Cronin AM, Katz IT, Howitt BE, Horowitz NS, Lee LJ, Wright AA. Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival. PLoS ONE 2018; 13:e0193047. PubMed
  • Wright AA, Raman N, Staples P, Schonholz S, Cronin A, Carlson K, Keating NL, Onnela JP. The HOPE Pilot Study: Harnessing Patient-Reported Outcomes and Biometric Data to Enhance Cancer Care. JCO Clin Cancer Inform 2018; 2:1-12. PubMed
  • Melamed A, Wright AA. Patient Reported Outcomes: Recent Successes and Future Opportunities. Gynecol Oncol 2018; 148:1-2. PubMed
  • Bober SL, Recklitis CJ, Michaud AL, Wright AA. Improvement in sexual function after ovarian cancer: Effects of sexual therapy and rehabilitation after treatment for ovarian cancer. Cancer 2017. PubMed
  • Kumar P, Wright AA, Hatfield LA, Temel JS, Keating NL. Family Perspectives on Hospice Care Experiences of Patients with Cancer. J Clin Oncol 2017; 35:432-439. PubMed
  • Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, Del Carmen MG, Keating NL. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database. JAMA Oncol 2017; 3:76-82. PubMed
  • Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, Cristea M, Griggs JJ, Levenback CF, Mantia-Smaldone G, Meyer LA, Matulonis UA, Niland JC, Sun C, O'Malley DM, Wright AA. Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol 2016. PubMed
  • Markt SC, Lago-Hernandez CA, Miller RE, Mahal BA, Bernard B, Albiges L, Frazier LA, Beard CJ, Wright AA, Sweeney CJ. Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. Cancer 2016; 122:3127-3135. PubMed
  • Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol 2016; 143:3-15. PubMed
  • Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34:3460-73. PubMed
  • Wright AA, Bohlke K, Edelson MI. Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: Society of Gynecologic Oncology and ASCO Clinical Practice Guideline Summary. J Oncol Pract 2016. PubMed
  • Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol 2016. PubMed
  • Wright AA, Keating NL, Ayanian JZ, Chrischilles EA, Kahn KL, Ritchie CS, Weeks JC, Earle CC, Landrum MB. Family Perspectives on Aggressive Cancer Care Near the End of Life. JAMA 2016; 315:284-92. PubMed
  • Meyer LA, Bohlke K, Powell MA, Fader AN, Franklin GE, Lee LJ, Matei D, Coallier L, Wright AA. Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol 2015. PubMed
  • Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol 2015; 33:2841-7. PubMed
  • Cohn DE, Havrilesky LJ, Osann K, Lipscomb J, Hsieh S, Walker JL, Wright AA, Alvarez RD, Karlan BY, Bristow RE, DiSilvestro PA, Wakabayashi MT, Morgan R, Mukamel DB, Wenzel L. Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice. Gynecol Oncol 2015. PubMed
  • Meyer LA, Bohlke K, Wright AA. Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Oncol Pract 2015. PubMed
  • Narang AK, Wright AA, Nicholas LH. Trends in Advance Care Planning in Patients With Cancer: Results From a National Longitudinal Survey. JAMA Oncol 2015. PubMed
  • Horowitz NS, Wright AA. Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. Gynecol Oncol 2015; 138:201-6. PubMed
  • Pirl WF, Greer JA, Irwin K, Lennes IT, Jackson VA, Park ER, Fujisawa D, Wright AA, Temel JS. Processes of discontinuing chemotherapy for metastatic non-small-cell lung cancer at the end of life. J Oncol Pract 2015. PubMed
  • Odejide OO, Salas Coronado DY, Watts CD, Wright AA, Abel GA. End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. J Oncol Pract 2014. PubMed
  • Wright AA, Hatfield LA, Earle CC, Keating NL. End-of-life care for older patients with ovarian cancer is intensive despite high rates of hospice use. J Clin Oncol 2014. PubMed
  • Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio L, Cibulskis K, Bertelsen B, Romero-Cordoba S, Treviño V, Vazquez-Santillan K, Guadarrama AS, Wright AA, Rosenberg MW, Duke F, Kaplan B, Wang R, Nickerson E, Walline HM, Lawrence MS, Stewart C, Carter SL, McKenna A, Rodriguez-Sanchez IP, Espinosa-Castilla M, Woie K, Bjorge L, Wik E, Halle MK, Hoivik EA, Krakstad C, Gabiño NB, Gómez-Macías GS, Valdez-Chapa LD, Garza-Rodríguez ML, Maytorena G, Vazquez J, Rodea C, Cravioto A, Cortes ML, Greulich H, Crum CP, Neuberg DS, Hidalgo-Miranda A, Escareno CR, Akslen LA, Carey TE, Vintermyr OK, Gabriel SB, Barrera-Saldaña HA, Melendez-Zajgla J, Getz G, Salvesen HB, Meyerson M. Landscape of genomic alterations in cervical carcinomas. Nature 2014; 506:371-5. PubMed
  • Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG. Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ 2014; 348:g1219. PubMed
  • Krishnan MS, Epstein-Peterson Z, Chen YH, Tseng YD, Wright AA, Temel JS, Catalano P, Balboni TA. Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: the TEACHH model. Cancer 2014. PubMed
  • Dizon DS, Ambrosio AJ, Feltmate C, Wright AA, Campos SM, Viswanathan A, . Pushing the bar in treatment of cervical cancer: what can comprehensive cancer centers do on their own? Gynecol Oncol 2013; 131:464-6. PubMed
  • Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT, Quick CM, Laury A, Katz IT, Hahn WC, Matulonis UA, Hirsch MS. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 2013; 119:3776-83. PubMed
  • Balboni TA, Balboni M, Enzinger AC, Gallivan K, Paulk ME, Wright A, Steinhauser K, VanderWeele TJ, Prigerson HG. Provision of spiritual support to patients with advanced cancer by religious communities and associations with medical care at the end of life. JAMA Intern Med 2013; 173:1109-17. PubMed
  • Krishnan M, Temel JS, Wright AA, Bernacki R, Selvaggi K, Balboni T. Predicting life expectancy in patients with advanced incurable cancer: a review. J Support Oncol 2013; 11:68-74. PubMed
  • Gao X, Prigerson HG, Diamond EL, Zhang B, Wright AA, Meyer F, Maciejewski PK. Minor cognitive impairments in cancer patients magnify the effect of caregiver preferences on end-of-life care. J Pain Symptom Manage 2013. PubMed
  • Shoni M, Parra-Herran CE, May T, Wright AA, Feltmate CM. Multiple synchronous primary gynecologic malignancies in an MSH2 mutation carrier with endometriosis. J Clin Oncol 2013; 31:e33-6. PubMed
  • Katz IT, Nkala B, Dietrich J, Wallace M, Bekker LG, Pollenz K, Bogart LM, Wright AA, Tsai AC, Bangsberg DR, Gray GE. A qualitative analysis of factors influencing HPV vaccine uptake in Soweto, South Africa among adolescents and their caregivers. PLoS ONE 2013; 8:e72094. PubMed
  • Wright AA, Stieglitz H, Kupersztoch YM, Paulk ME, Kim Y, Katz IT, Munoz F, Jimenez RB, Mutchler J, Rivera L, Back AL, Prigerson HG. United states acculturation and cancer patients' end-of-life care. PLoS ONE 2013; 8:e58663. PubMed
  • Maciejewski PK, Phelps AC, Kacel EL, Balboni TA, Balboni M, Wright AA, Pirl W, Prigerson HG. Religious coping and behavioral disengagement: opposing influences on advance care planning and receipt of intensive care near death. 2012. PubMed
  • Wright AA, Keating NL, Balboni TA, Matulonis UA, Block SD, Prigerson HG. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. J Clin Oncol 2010; 28:4457-64. PubMed
  • Wright AA, Mack JW, Kritek PA, Balboni TA, Massaro AF, Matulonis UA, Block SD, Prigerson HG. Influence of patients' preferences and treatment site on cancer patients' end-of-life care. Cancer 2010; 116:4656-63. PubMed
  • Mack JW, Weeks JC, Wright AA, Block SD, Prigerson HG. End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol 2010; 28:1203-8. PubMed
  • Zhang B,Wright AA,Huskamp HA,Nilsson ME,Maciejewski ML,Earle CC,Block SD,Maciejewski PK,Prigerson HG. Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med 2009; 169:480-8. PubMed
  • Wright AA,Zhang B,Ray A,Mack JW,Trice E,Balboni T,Mitchell SL,Jackson VA,Block SD,Maciejewski PK,Prigerson HG. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 2008; 300:1665-73. PubMed
  • Wright AA, Katz IT. Letting go of the rope--aggressive treatment, hospice care, and open access. N Engl J Med 2007; 357:324-7. PubMed
  • Katz IT, Wright AA. Preventing cervical cancer in the developing world. N Engl J Med 2006; 354:1110. PubMed
  • Parikh RB, Wright AA. The Affordable Care Act and End-of-Life Care for Patients With Cancer. Cancer J ; 23:190-193. PubMed
Hide